About HiberCell
HiberCell is a company based in New York (United States) founded in 2015. It operates as a HealthTech. HiberCell has raised $128.15 million across 3 funding rounds from investors including Mount Sinai, Hercules Capital and Celgene. HiberCell has completed 1 acquisition, including Genuity Science. HiberCell offers products and services including HC-7366, HC-5404, and Odetiglucan. HiberCell operates in a competitive market with competitors including TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hibercell Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$128.15 M (USD)
in 3 rounds
-
Latest Funding Round
$30 M (USD), Debt – Conventional
May 19, 2021
-
Investors
Mount Sinai
& 10 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of HiberCell
HiberCell offers a comprehensive portfolio of products and services, including HC-7366, HC-5404, and Odetiglucan.
Designed to activate GCN2 kinase for stress response.
Developed to inhibit PERK for stress mitigation pathways.
Formulated to modulate immune response in tumor microenvironment.
People of HiberCell
Unlock access to complete
Unlock access to complete
Funding Insights of HiberCell
HiberCell has successfully raised a total of $128.15M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $30 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in HiberCell
HiberCell has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Mount Sinai, Hercules Capital and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Magnetic Ventures is focused on transforming healthcare through AI and biotech investments.
|
Locked | Locked | Locked |
Investor details for HiberCell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HiberCell
HiberCell has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Genuity Science.
Investment portfolio details for HiberCell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AI-based omics data analysis solutions are provided to researchers.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for HiberCell
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - HiberCell
Detailed financials for HiberCell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hibercell Comparisons
Peer comparison for HiberCell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HiberCell
HiberCell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer are developed by targeting ecDNA.
|
|
| Locked | Locked | Locked |
T-cell therapies for cancer treatment are developed by Bolt Biotherapeutics.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of HiberCell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hibercell
Complete news archive for HiberCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HiberCell
HiberCell was founded in 2015 and raised its 1st funding round 4 years after it was founded.
HiberCell is headquartered in New York, United States. It is registered at New York, New York, United States.
HiberCell is a funded company, having raised a total of $128.15M across 3 funding rounds to date.
HiberCell is engaged in pioneering cancer treatment paradigms by targeting adaptive stress mechanisms in tumors. The company is dedicated to addressing treatment resistance, relapse, and metastasis through innovative therapeutic candidates like HC-7366, HC-5404, and Odetiglucan. These solutions are designed to exploit stress-driven vulnerabilities in cancer cells, inhibit stress-mitigating pathways, and enhance immune responses in the tumor microenvironment. Operations are centered in the healthcare and biotechnology sector with a focus on improving patient outcomes through advanced clinical development.
HiberCell's top competitors include Lyell Immunopharma, GigaGen and Shattuck Labs.
HiberCell offers HC-7366, HC-5404, and Odetiglucan.
HiberCell has made 1 acquisition, including Genuity Science.
HiberCell has 11 investors. Key investors include Mount Sinai, Hercules Capital, Celgene, Arch Venture Partners, and Bristol-Myers Squibb.